Literature DB >> 6428982

Refractory duodenal ulcer.

K D Bardhan.   

Abstract

A refractory duodenal ulcer was arbitrarily defined as one that had failed to heal completely after treatment with cimetidine 1 g daily for three months. Of 66 patients with refractory duodenal ulcer, healing eventually occurred in 37 patients, after treatment for an average of 7.4 months. But 28 patients did not heal despite treatment for an average of 9.4 months; and one patient defaulted. In 41 patients the daily dose of cimetidine was increased to 2 g: the ulcers in 31 patients healed. In eight patients the daily dose was increased to 3 g and healing occurred in four patients. Eighteen patients required admission on 22 occasions because of severe symptoms despite treatment. Nine patients underwent surgery but in five the results were poor. Differences in clinical and endoscopic features between refractory and non-refractory ulcer patients were small. Acid and pepsin secretion were similar and gastrin concentrations normal. Blood levels of the drug and suppression of acid secretion were both satisfactory. Identification of refractory ulcer patients at the start of treatment was therefore not possible. Refractoriness could occur at any time during the course of the disease, previous treatment with cimetidine often having resulted in rapid healing, but subsequent relapses were also usually refractory. The cause of refractoriness remains unknown and the rather poor results of surgery in this series suggests that optimal management of these patients remains to be determined. Refractoriness probably indicates a changed natural history of the disease and in some patients a more poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428982      PMCID: PMC1432597          DOI: 10.1136/gut.25.7.711

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  An assessment of the radial diffusion method for the measurement of pepsin in gastric secretion and its comparison with the haemoglobin substrate colorimetric method.

Authors:  M Ishague; K D Bardhan
Journal:  Clin Chim Acta       Date:  1978-07-15       Impact factor: 3.786

2.  Short- and long-term treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine.

Authors:  G Bodemar; B Norlander; A Walan; R Larsson
Journal:  Scand J Gastroenterol Suppl       Date:  1979

3.  Women and duodenal ulcer.

Authors:  G Bianchi Porro; A Prada; M Petrillo; M Lazzaroni
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-18

4.  Women and duodenal ulcer.

Authors:  N R Peden; E J Boyd; K G Wormsley
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-14

5.  Duodenal ulcer in servicemen.

Authors:  B G Hannigan
Journal:  J R Army Med Corps       Date:  1980-10       Impact factor: 1.285

6.  Clinical and pharmacological effectiveness of cimetidine in duodenal ulcer patients.

Authors:  S J Ruen; P Hesselfeldt; N E Larsen
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

7.  Cimetidine-a clinical and pharmacokinetic study.

Authors:  J Webster; H E Barber; G M Hawksworth; T A Jeffers; J Petersen; J C Petrie; P W Brunt; N A Mowat; R Griffiths
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  Report on the United States experience with cimetidine in Zollinger-Ellision syndrome and other hypersecretory states.

Authors:  D M McCarthy
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

9.  Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment.

Authors:  S Massarrat; A Eisenmann
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

10.  Cimetidine plasma concentration-response relationships.

Authors:  R Gugler; G Fuchs; M Dieckmann; A A Somogyi
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  27 in total

1.  Peptic ulcer disease. Pathophysiology and current medical management.

Authors:  B F Scharschmidt
Journal:  West J Med       Date:  1987-06

2.  Gastric acid secretion stimulated by modified sham-feeding, and the effects of histamine H2-antagonist and anti-muscarinic agent in patients with duodenal ulcer.

Authors:  S Ooi; E Kaneko
Journal:  Gastroenterol Jpn       Date:  1989-10

3.  The pathophysiology of peptic ulcer disease.

Authors:  F P Brooks
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

4.  The surgical treatment of peptic ulcer disease. A physician's view.

Authors:  J P Bader
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Low dose maintenance treatment with cimetidine in duodenal ulcer: intermediate-term results.

Authors:  K D Bardhan; R F Hinchliffe; K Bose
Journal:  Postgrad Med J       Date:  1986-05       Impact factor: 2.401

6.  Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.

Authors:  G Bianchi Porro; F Parente; M Lazzaroni
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

7.  Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

Authors:  A H Briggs; M J Sculpher; R P Logan; J Aldous; M E Ramsay; J H Baron
Journal:  BMJ       Date:  1996-05-25

8.  Prognosis of chronic duodenal ulcer: a prospective study of the effects of demographic and environmental factors and ulcer healing.

Authors:  R W Nasiry; J H McIntosh; K Byth; D W Piper
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

9.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

10.  Cigarette smoking and duodenal ulcer.

Authors:  D H Hull; P J Beale
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.